Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)

Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A
Vaccine Healive(R)

BEIJING, Nov. 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a
leading developer and provider of vaccines, announced today that it was
selected by the Shanghai Government to supply its inactivated hepatitis A
vaccine, Healive, to the public market of Shanghai. Out of the five vaccine
manufacturers that participated in the bidding process, the Shanghai
Government awarded Sinovac the entire hepatitis A vaccine purchase order,
valued at RMB 20.6 million, or approximately $3 million. Pursuant to the
agreement, Sinovac will supply Healive over the next twelve months.

The purchase plan from the Shanghai Government reflects the continued
expansion of government purchase programs for vaccines. This is part of the
national expanded immunization program (EPI) funded by the Chinese government.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "We are
pleased that the Shanghai Government selected Sinovac as the sole manufacturer
for this $3 million hepatitis A tender offer. Earlier this year, we
established growth for Healive in both the public and private pay markets as a
strategic goal. At that time, our newly completed filling and packaging plant
had made us well positioned to fulfill existing orders, increase our
production scale for meeting the demand from both public market and private
market and develop new vaccines. We have done just that, securing large
Healive purchase orders from the Shanghai government and China's Ministry of
Public Health, even as we quickly adapted to develop and commercialize
PANFLU.1, a time sensitive H1N1 vaccine. The selection confirms our ability
to supply our high quality vaccines pursuant to the Government purchasing
programs."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on the research, development, manufacture and commercialization of vaccines
that protect against human infectious diseases. Sinovac's commercialized
vaccine products include Healive® (hepatitis A), Bilive® (combined hepatitis A
and B), Anflu® (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)),
and PANFLU.1(TM) (pandemic influenza A (H1N1)). Sinovac is developing
vaccines for enterovirus 71, universal pandemic influenza, pneumococcal
infection, Japanese encephalitis, and human rabies. Its wholly owned
subsidiary, Tangshan Yian, is conducting field trials for independently
developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are
not historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to
update any forward-looking statement, except as required under applicable law.

Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Email: info@sinovac.com

Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com

Media
Janine McCargo
The Ruth Group
Tel: 656-536-7033
Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Co., Ltd.

Helen G. Yang of Sinovac Biotech Ltd., Tel: +86-10-8289-0088 x9871, Fax:
+86-10-6296-6910, or info@sinovac.com; Investors, Amy Glynn, +1-646-536-7023,
or aglynn@theruthgroup.com, or Stephanie Carrington, +1-646-536-7017, or
scarrington@theruthgroup.com, or Media, Janine McCargo, +1-656-536-7033, or
jmccargo@theruthgroup.com, all of The Ruth Group for Sinovac Biotech Ltd.